Effect of Liraglutide on Type B Insulin Resistance Syndrome and Insulin Allergy in Type 2 Diabetes: A Case Report

<p><strong>Article full text</strong></p> <p><br> The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0291-2"><b>here</b>.</a><br> <br> <strong>Provide enhanced content for this article</strong><br> If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <u>[email protected]</u>.<br> <br> The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.<br> <br> Other enhanced features include, but are not limited to:<br> • Slide decks<br> • Videos and animations<br> • Audio abstracts<br> • Audio slides</p> <p> </p> <p> </p

Clinical characteristics of the participants with CKD stages G1–G3.

<p>BMI, body mass index; DM, diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; S-P, serum phosphate; U-P, 24-h urinary excretion of phosphate; S-Ca, serum calcium; 25OH vitD, 25-hydroxyvitamin D3; iPTH, intact parathyroid hormone; eGFR, estimated glomerular filtration rate; U-albumin, urinary albumin.</p

Comparisons of serum FGF23 (pg/mL).

<p>(<b>A</b>) and Nephron index (<b>B</b>) in chronic kidney disease stages G1, G2, and G3 in diabetic patients. *<i>p</i> < 0.05 vs. G1, **<i>p</i> < 0.01 vs. G1, #<i>p</i> < 0.01 vs. G2, <i>p</i> < 0.01 by post hoc analysis (Holm test) after Kruskal-Wallis test (<i>p</i> < 0.001).</p

Simple regression analyses of serum P.

<p>(<b>A</b>), Ln intact PTH (<b>B</b>), Ln FGF23 (<b>C</b>), and Ln Nephron index (<b>D</b>) with eGFR in diabetic patients. Pearson’s correlation coefficients were calculated. FGF23, fibroblast growth factor 23; Ln, logarithmic value.</p

Different clinical parameters for hemodialysis patients with and without diabetes mellitus.

<p>Different clinical parameters for hemodialysis patients with and without diabetes mellitus.</p

Correlation between hemodialysis duration and rSO₂.

<p>Correlation between hemodialysis duration and rSO₂.</p

Patients Characteristics and the correlation between cerebral rSO₂ and clinical parameters.

<p>Patients Characteristics and the correlation between cerebral rSO₂ and clinical parameters.</p

Comparison of cerebral rSO₂ in hemodialysis patients (HD) with and without diabetes mellitus (DM).

<p>* < 0.05 at HD patients with DM vs. those without DM.</p

Multivariate linear regression analysis: Independent factors of cerebral rSO₂ in hemodialysis patients.

<p>Multivariate linear regression analysis: Independent factors of cerebral rSO₂ in hemodialysis patients.</p